Treatment of a Woman with Inoperable Meningioma Using Mifepristone for 26 Years.

IF 0.9 Q4 CLINICAL NEUROLOGY Case Reports in Neurological Medicine Pub Date : 2020-02-11 eCollection Date: 2020-01-01 DOI:10.1155/2020/5162918
Maria das Dores Medina-Lopes, Luiz Augusto Casulari
{"title":"Treatment of a Woman with Inoperable Meningioma Using Mifepristone for 26 Years.","authors":"Maria das Dores Medina-Lopes, Luiz Augusto Casulari","doi":"10.1155/2020/5162918","DOIUrl":null,"url":null,"abstract":"<p><p>Meningioma treatment includes observation of its growth or surgery with or without associated radiotherapy. However, drug treatment can be used for tumors deemed inoperable because of their size and location. Due to the presence of progesterone receptors, the use of antiprogestin mifepristone is recommended. This study describes a case of inoperable meningioma treated with mifepristone for 26 years without interruption. The patient is a 45-year-old woman diagnosed with plaque meningioma, extending from the bottom of her right orbit, through the length of the small wing of the sphenoid, part of the large wing of the sphenoid, especially near the superior orbital fissure, and at the ceiling of the orbit. As this meningioma was considered inoperable, treatment with 200 mg oral mifepristone was administered uninterruptedly for 26 years. This treatment initially halted the growth of the meningioma and subsequently resulted in a small reduction of its volume; however, the meningioma has persisted until the last evaluation. After five years of mifepristone use, hydroxyurea was added for nine months but was discontinued due to anemia and leucopenia. In conclusion, mifepristone was useful for the survival of the patient for those 26 years. The drug interfered with the natural history of the meningioma, which generally evolves to death in such long follow-up durations without associated surgery or radiation therapy.</p>","PeriodicalId":9615,"journal":{"name":"Case Reports in Neurological Medicine","volume":"2020 ","pages":"5162918"},"PeriodicalIF":0.9000,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036131/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Neurological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/5162918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Meningioma treatment includes observation of its growth or surgery with or without associated radiotherapy. However, drug treatment can be used for tumors deemed inoperable because of their size and location. Due to the presence of progesterone receptors, the use of antiprogestin mifepristone is recommended. This study describes a case of inoperable meningioma treated with mifepristone for 26 years without interruption. The patient is a 45-year-old woman diagnosed with plaque meningioma, extending from the bottom of her right orbit, through the length of the small wing of the sphenoid, part of the large wing of the sphenoid, especially near the superior orbital fissure, and at the ceiling of the orbit. As this meningioma was considered inoperable, treatment with 200 mg oral mifepristone was administered uninterruptedly for 26 years. This treatment initially halted the growth of the meningioma and subsequently resulted in a small reduction of its volume; however, the meningioma has persisted until the last evaluation. After five years of mifepristone use, hydroxyurea was added for nine months but was discontinued due to anemia and leucopenia. In conclusion, mifepristone was useful for the survival of the patient for those 26 years. The drug interfered with the natural history of the meningioma, which generally evolves to death in such long follow-up durations without associated surgery or radiation therapy.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用米非司酮治疗无法手术的脑膜瘤妇女 26 年。
脑膜瘤的治疗方法包括观察其生长情况或进行手术,同时进行或不进行放射治疗。然而,药物治疗可用于因肿瘤大小和位置而被认为无法手术的肿瘤。由于存在孕酮受体,建议使用抗孕激素米非司酮。本研究描述了一例无法手术的脑膜瘤患者,她接受米非司酮治疗 26 年,从未间断。患者是一名 45 岁女性,被诊断为斑块状脑膜瘤,瘤体从右眼眶底部延伸,穿过蝶骨小翼的长度、蝶骨大翼的一部分,尤其是在眶上裂附近和眼眶顶。由于该脑膜瘤被认为无法手术,医生不间断地口服 200 毫克米非司酮治疗了 26 年。这种治疗最初阻止了脑膜瘤的生长,随后使其体积略有缩小;然而,直到最近一次评估,脑膜瘤仍然存在。在使用米非司酮 5 年后,又加用了 9 个月的羟基脲,但因贫血和白细胞减少而停用。总之,米非司酮有助于患者在这 26 年中存活。该药物干扰了脑膜瘤的自然病史,在没有相关手术或放射治疗的情况下,脑膜瘤一般会在如此长的随访时间内发展到死亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
26
审稿时长
11 weeks
期刊最新文献
Disseminated Intracranial and Spinal Neurenteric Cysts: A Case Report and Literature Review. New-Onset Focal to Bilateral Tonic-Clonic Seizure Following COVID-19 Vaccination. Endotracheal Oxygen Insufflation Associated with Life-Threatening Barotrauma during Apnea Testing. Severe Neurotoxicity due to Atropa belladonna Poisoning: A Case Report and Literature Review. Rhabdomyolysis Induced by Levetiracetam: A Case Report in Kuwait.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1